The effect of low-carbohydrate diets on serum concentration of soluble adhesion molecules: a systematic review and meta-analysis of randomized controlled trials.

Int J Environ Health ResApr 21, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Mahdieh Khodarahmi, Sanaz Mehrabani, Gholamreza Askari

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of low-carbohydrate diets (LCDs) on serum levels of adhesion molecules in adults. Analyzing data from nine randomized controlled trials with 333 participants, the study found that LCDs significantly reduced E-selectin concentrations by 3.95 ng/mL compared to controls (95% CI: -6.42 to -1.47; P = 0.002).

Key findings

  • LCDs significantly reduced E-selectin concentrations by 3.95 ng/mL compared to control groups.
  • No significant effects were observed on ICAM, VCAM, or P-selectin levels.
  • The analysis included nine publications with a total of 333 participants.
  • No heterogeneity was found in the results (I² = 0.0%).

Why it matters

Understanding the effects of dietary interventions on adhesion molecules is crucial, as they play a role in cardiovascular disease. This research suggests that LCDs may offer a beneficial effect on E-selectin levels, potentially influencing cardiovascular health.

What to keep in mind

Given limited studies and dietary heterogeneity, findings should be interpreted cautiously.

Source

Published in Int J Environ Health Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.